Saralasin TFA [Sar1,Ala8] Angiotensin II TFA|西域试剂

Saralasin TFA [Sar1,Ala8] Angiotensin II TFA,98.98%

产品编号：Bellancom-P0205B| 分子式：C₄₄H₆₆F₃N₁₃O₁₂| 分子量：1026.07

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P0205B		￥3500.00	杭州北京（现货）
Bellancom-P0205B		￥5800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Saralasin TFA [Sar1,Ala8] Angiotensin II TFA

产品介绍

Saralasin ([Sar1,Ala8] Angiotensin II) TFA 是血管紧张素 II (angiotensin II) 的八肽类似物。Saralasin TFA 是一种竞争性的血管紧张素 II 受体 (angiotensin II receptor) 拮抗剂，K_i 值为 0.32 nM (74% 的结合位点)，并具有部分激动剂活性。Saralasin TFA 可用于肾血管性高血压、肾素依赖性（血管紧张素原性）高血压的相关研究。

生物活性

Saralasin ([Sar1,Ala8] Angiotensin II) TFA is an octapeptide analog of angiotensin II. Saralasin TFA is a competitive angiotensin II receptor antagonist with a K_i value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin TFA can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension^[6].

体外研究

Saralasin TFA (1 nM, 48 or 72 h) inhibits cell growth in 3T3 and SV3T3 cells.
Saralasin TFA (5 μM, 2h) restores I_{to, fast} (Fast-Inactivating Transient Outward K+ Current in Mouse Ventricle) and I K, slow (Slow-Inactivating Transient Outward K+ Current in Mouse Ventricl) to control levels in myocytes.
Saralasin TFA (0.1-10 nM, 40 min) inhibits binding of FITC-Ang II to rat liver membrane preparation (used as the source of angiotensin receptors) with a K_i value of 0.32 nM for 74% of the binding sites and 2.7 nM for the remaining binding sites.
Saralasin TFA (1 μM, perfused rat ovary in vitro) inhibits the ovulation rate versus control and reduces prostaglandin E2 and 6-keto-prostaglandin F_1α levels^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	3T3 and SV3T3 cells
Concentration:	1 nM
Incubation Time:	48 h, 72 h
Result:	Inhibited cell growth in 3T3 and SV3T3 cells and caused an increase of cellular renin concentration.

体内研究
(In Vivo)

Saralasin TFA (intravenous injection, 5-50 μg/kg, a single dose) ameliorates the oxidative stress and tissue injury in cerulein-induced pancreatitis^[5].
Saralasin TFA (subcutaneous injection, 10 and 30 mg/kg, a single dose) increases serum renin activity (SRA) in normal, conscious rats, without markedly altering blood pressure or heart rate^[6].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Cerulein-induced acute pancreatitis rats model^[5]
Dosage:	5, 10, 20, and 50 μg/kg, a single dose.
Administration:	Intravenous injection
Result:	Restored the pancreatic morphological characteristics to the control level. Reduced pancreatic injury and suppressed the glutathione depletion induced by cerulean.

Animal Model:	Male Sprague-Dawley rats^[6]
Dosage:	10 and 30 mg/kg, a single dose.
Administration:	Subcutaneous injection
Result:	Stimulated renin release without altering blood pressure or heart rate at the time of measuring serum renin levels 20 minutes after injection.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Cerulein-induced acute pancreatitis rats model^[5]
Dosage:	5, 10, 20, and 50 μg/kg, a single dose.
Administration:	Intravenous injection
Result:	Restored the pancreatic morphological characteristics to the control level. Reduced pancreatic injury and suppressed the glutathione depletion induced by cerulean.

Animal Model:	Male Sprague-Dawley rats^[6]
Dosage:	10 and 30 mg/kg, a single dose.
Administration:	Subcutaneous injection
Result:	Stimulated renin release without altering blood pressure or heart rate at the time of measuring serum renin levels 20 minutes after injection.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Cerulein-induced acute pancreatitis rats model^[5]
Dosage:	5, 10, 20, and 50 μg/kg, a single dose.
Administration:	Intravenous injection
Result:	Restored the pancreatic morphological characteristics to the control level. Reduced pancreatic injury and suppressed the glutathione depletion induced by cerulean.

Animal Model:	Male Sprague-Dawley rats^[6]
Dosage:	10 and 30 mg/kg, a single dose.
Administration:	Subcutaneous injection
Result:	Stimulated renin release without altering blood pressure or heart rate at the time of measuring serum renin levels 20 minutes after injection.

性状

Solid

溶解性数据

In Vitro:

H₂O : 100 mg/mL (97.46 mM; Need ultrasonic)

DMSO : 50 mg/mL (48.73 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.9746 mL	4.8730 mL	9.7459 mL
5 mM	0.1949 mL	0.9746 mL	1.9492 mL
10 mM	0.0975 mL	0.4873 mL	0.9746 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： PBS
Solubility: 100 mg/mL (97.46 mM); Clear solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (2.44 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.44 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
3.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (2.44 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.44 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
4.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (2.44 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.44 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。